Infectious Disease Control

Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an expected enrollment of 30 subjects HANGZHOU, China and SHAOXING, China, June 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been ...

2022-06-28 18:11 3694

JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5

TIANJIN, China, June 27, 2022 /PRNewswire/ -- As the SARS-COV-2 Omicron subvariants BA.4 and BA.5 make their way across the EU and the US, Joysbio is able to give people the power to administer a rapid test for themselves at home. The Joysbio Coronavirus Antigen Rapid Test Kit can effectively det...

2022-06-27 15:30 4343

Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines

TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-19 vaccine ("R520A"), from the Food and Drug Administration ofthe P...

2022-06-27 14:47 4741

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

* Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 inEurope * Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechn...

2022-06-24 03:24 5439

GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION

– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV– SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed ...

2022-06-16 11:15 3011

WHO visit photos unveiled - BGI Genomics supports post-pandemic recovery in Hong Kong

SHENZHEN, China, June 15, 2022 /PRNewswire/ -- World Health Organization (WHO) has recently unveiled photos from its Feb-Mar 2021 visit to Hong Kong as COVID-19 affected the city, covering community testing facilities in key locations such as the Hong Kong International Airport and the Morse Park...

2022-06-15 09:24 3978

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...

2022-06-13 21:20 4319

EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax,a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R4...

2022-06-11 03:15 7503

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 4784

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...

2022-06-08 09:23 4300

Vazyme Releases 2021 Annual Report: Announces More Efforts in Technology innovation and Together with Partners for a Better Future

NANJING, China, June 2, 2022 /PRNewswire/ -- Vazyme, China's leading biotechnology company, has recently released its 2021 annual report, revealing that the company has maintained a steady and solid growth throughout the past year. The report shows that it has achieved$289 million in operating in...

2022-06-02 12:54 4625

Kemin Food Technologies - Asia Introduces Antimicrobial Disinfectant Solutions KEEPER™ and OXINE™

Latest product lines address safety at the start by treating food, water and the preparation space for food SINGAPORE, June 1, 2022 /PRNewswire/ -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world w...

2022-06-01 08:00 4328

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

TAIPEI, May 27, 2022 /PRNewswire/ -- Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best neutralization a...

2022-05-27 11:40 3530

ScentAir Steps Up Efforts to Address Customers' Concern Over Air Quality

HONG KONG, May 26, 2022 /PRNewswire/ -- ScentAir, the scent marketing leader, continues to lead the way in helping brands globally address customers' concerns, as cases surge inChina amid lockdowns.

2022-05-26 17:26 5941

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 3154

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 6488

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. Insi...

2022-05-24 21:00 3796

New Study Shows Critical Role of 1,5-Anhydroglucitol (1,5-AG) in COVID-19 Pathogenesis by Binding to the COVID-19 Spike Protein

Study Findings Support Data Presented on the GlycoMark Blood Test at the Most RecentADA and AHA Scientific Sessions  RALEIGH, N.C., May 24, 2022 /PRNewswire/ -- Precision Diabetes, Inc. A new study recently published inNature Metabolism shows that 1,5-anhydroglucitol (1,5-AG), a glucose-like me...

2022-05-24 19:00 2105

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL") for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5...

2022-05-19 23:28 4949

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...

2022-05-19 04:56 5146
1 ... 11121314151617 ... 24